Navigation Links
Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Date:5/13/2009

NERVIANO, Italy, May 13 /PRNewswire/ -- The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly efficient and well tolerated in preclinical models of cancer after repeated dosing. This unique inhibitor adds another promising candidate to the pipeline of innovative cell cycle targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in April. NMS CDK and Aurora inhibitors are in phase I and II clinical development, respectively, and are starting to show promising activity in specific patient populations.

The clinical development path foresees application of the NMS PLK-1 inhibitor in solid and hematological indications. "I am pleased to see the second IND approval this year and I highly appreciate the consistant delivery of high quality clinical candidates by the Nerviano site" comments Dr. Francesco Colotta, VP R&D at NMS.

Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions.

    For information:

    Nerviano Medical Sciences
    Maria D'Acquino,
    tel +39-0331-581013,
    mob. +39-335-1863051,
    maria.dacquino@nervianoms.com



'/>"/>
SOURCE Nerviano Medical Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
3. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
4. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
5. ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoracic Surgeons
6. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
7. Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
8. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
9. Nfocus Neuromedical Appoints Robert OHolla to Head Regulatory
10. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
11. BioMS Medical to present at Alberta Economic Forum in Geneva
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... 2016 ReportsnReports.com adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):